Business

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Financial Post · September 18, 2026 at 4:37 p.m.

PARSIPPANY, N.J., Sept.

18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years).

The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

More from Financial Post

Paladin Announces Availability of Notice of Meeting for Annual General Meeting

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

More in Business

Paladin Announces Availability of Notice of Meeting for Annual General Meeting

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

David Pearson Appointed President of Anthem Properties Group

AGI Third Quarter 2026 Results Release Date and Conference Call